Market Overview:
The global chronic phase marker market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of chronic diseases, rising demand for early diagnosis and treatment, and technological advancements in the field of diagnostics. Based on type, the global chronic phase marker market is segmented into tumor markers, cardiac markers, thyroid markers, and others. Tumor markers are further sub-segmented into prostate-specific antigen (PSA), human chorionic gonadotropin (hCG), carcinoembryonic antigen (CEA), and others. Cardiac markers are further sub-segmented into troponin I & T (TnI & TnT), B-type natriuretic peptide (BNP), myoglobin (Mb) creatinine kinase MB isoenzyme (CKMB). and triiodothyronine uptake test kit(TT3Uptake). Others include renal function tests such as blood urea nitrogen levels ([BUN]), serum creatinine levels ([Cr]), estimated glomerular filtration rate([eGFR]) etc.
Product Definition:
A chronic phase marker is a protein that is produced in large quantities by cancer cells during the early stages of the disease, when it is still considered to be manageable. The presence of these markers can help doctors to diagnose cancer early on and determine what treatment options are available.
Tumor Markers:
Tumor markers are substances released by tumors into the bloodstream. They can be either naturally occurring or artificially created chemical compounds. The most common tumor marker is called asos-B; it is a type of sugar found in cancer cells that enables the pathologist to distinguish between normal and cancer cells.
Cardiac Markers:
Cardiac markers are substances that are released by the heart during stress or excitement and can be used to measure the severity of a disease. The most common cardiac markers are enzymes such as troponin, myosin, and others which act as muscle relaxants that prevent further damage to heart muscles after an injury.
Application Insights:
The market is segmented based on application into hospitals, clinics, and diagnostic laboratories. Hospitals held the largest share in 2017 owing to the presence of a large number of players involved in R&D for developing new products for chronic phase marker applications. Furthermore, increasing investments by governments as well as private companies are expected to boost product development over the forecast period.
Clinical trials are an important part of drug development process and play a significant role in gaining approval from regulatory authorities such as FDA (U.S.) or EMA (Europe). The growing trend towards conducting clinical trials at global level through internet portals has become popular due to ease and convenience associated with it along with reduced cost involved in conducting such studies from remote locations across various parts of the world.
Regional Analysis:
North America dominated the global chronic phase marker market in 2017. This can be attributed to the presence of key players, high adoption rate of advanced diagnostic technologies and well-established healthcare infrastructure. In addition, rising prevalence of cancer is expected to drive regional growth over the forecast period. For instance, according to data published by American Cancer Society in 2018, 1 out of 6 men and 1 out of 4 women will be diagnosed with cancer during their lifetime in U.S., resulting into a huge economic burden on society every year.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing geriatric population base coupled with growing target disease incidence rates such as breast cancer and CVDs among others due to changing lifestyle habits such as smoking and alcohol consumption which are positively associated with chronic diseases development process respectively (Global Burden Disease).
Growth Factors:
- Increasing incidence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily due to the changing lifestyles and dietary habits of people across the world. As a result, there is an increased demand for diagnostic tests and therapies for chronic diseases.
- Growing awareness about early diagnosis and treatment: There is a growing awareness among people about the importance of early diagnosis and treatment of chronic diseases. This has led to an increase in the demand for diagnostic tests and therapies for chronic diseases.
- Technological advancements in diagnostics: There have been significant advancements in diagnostics technologies in recent years, which has led to improved accuracy in detection of Chronic Phase Markers (CPMs). This has resulted in an increase in their use for diagnosis of various types of cancer patients worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Phase Marker Market Research Report
By Type
Tumor Markers, Cardiac Markers, Thyroid Markers, Others
By Application
Hospitals, Clinics, Diagnostic Laboratories
By Companies
Nordic BioSite, DiaSorin, Roche, Bristol-Myers Squibb, Hologic, QIAGEN, Philips, Johnson & Johnson, Lifesign, Natus, BrainScope
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
225
Number of Tables & Figures
158
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Phase Marker Market Report Segments:
The global Chronic Phase Marker market is segmented on the basis of:
Types
Tumor Markers, Cardiac Markers, Thyroid Markers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Diagnostic Laboratories
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Nordic BioSite
- DiaSorin
- Roche
- Bristol-Myers Squibb
- Hologic
- QIAGEN
- Philips
- Johnson & Johnson
- Lifesign
- Natus
- BrainScope
Highlights of The Chronic Phase Marker Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tumor Markers
- Cardiac Markers
- Thyroid Markers
- Others
- By Application:
- Hospitals
- Clinics
- Diagnostic Laboratories
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Phase Marker Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic phase marker is a term used to describe a biomarker that is associated with an extended period of disease activity.
Some of the major companies in the chronic phase marker market are Nordic BioSite, DiaSorin, Roche, Bristol-Myers Squibb, Hologic, QIAGEN, Philips, Johnson & Johnson, Lifesign, Natus, BrainScope.
The chronic phase marker market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Phase Marker Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Phase Marker Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Phase Marker Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Phase Marker Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Phase Marker Market Size & Forecast, 2018-2028
4.5.1 Chronic Phase Marker Market Size and Y-o-Y Growth
4.5.2 Chronic Phase Marker Market Absolute $ Opportunity
Chapter 5 Global Chronic Phase Marker Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chronic Phase Marker Market Size Forecast by Type
5.2.1 Tumor Markers
5.2.2 Cardiac Markers
5.2.3 Thyroid Markers
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chronic Phase Marker Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chronic Phase Marker Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Diagnostic Laboratories
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Phase Marker Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Phase Marker Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chronic Phase Marker Analysis and Forecast
9.1 Introduction
9.2 North America Chronic Phase Marker Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chronic Phase Marker Market Size Forecast by Type
9.6.1 Tumor Markers
9.6.2 Cardiac Markers
9.6.3 Thyroid Markers
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chronic Phase Marker Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Diagnostic Laboratories
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chronic Phase Marker Analysis and Forecast
10.1 Introduction
10.2 Europe Chronic Phase Marker Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chronic Phase Marker Market Size Forecast by Type
10.6.1 Tumor Markers
10.6.2 Cardiac Markers
10.6.3 Thyroid Markers
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chronic Phase Marker Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Diagnostic Laboratories
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chronic Phase Marker Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chronic Phase Marker Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chronic Phase Marker Market Size Forecast by Type
11.6.1 Tumor Markers
11.6.2 Cardiac Markers
11.6.3 Thyroid Markers
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chronic Phase Marker Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Diagnostic Laboratories
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chronic Phase Marker Analysis and Forecast
12.1 Introduction
12.2 Latin America Chronic Phase Marker Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chronic Phase Marker Market Size Forecast by Type
12.6.1 Tumor Markers
12.6.2 Cardiac Markers
12.6.3 Thyroid Markers
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chronic Phase Marker Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Diagnostic Laboratories
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chronic Phase Marker Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chronic Phase Marker Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chronic Phase Marker Market Size Forecast by Type
13.6.1 Tumor Markers
13.6.2 Cardiac Markers
13.6.3 Thyroid Markers
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chronic Phase Marker Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Diagnostic Laboratories
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Phase Marker Market: Competitive Dashboard
14.2 Global Chronic Phase Marker Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Nordic BioSite
14.3.2 DiaSorin
14.3.3 Roche
14.3.4 Bristol-Myers Squibb
14.3.5 Hologic
14.3.6 QIAGEN
14.3.7 Philips
14.3.8 Johnson & Johnson
14.3.9 Lifesign
14.3.10 Natus
14.3.11 BrainScope
